Global Eye Cancer Market Expected To Reach At A Healthy Cagr Of 8.3{02346bf83de6e36140f9a3419962accbe3517f5478f0c39703bb0046727acb31} Till 2027

The MarketWatch News Department was not involved in the creation of this content.

Jan 02, 2021 (Heraldkeepers) — Eye cancers or ocular cancers manifests itself in the eye. Cancer is referred to the uncontrolled growth of the cells, similarly, eye cancer occurs when healthy cells in or around the eye change and grow uncontrollably leading to the formation of tumors. The global eye cancer market is expecting a healthy growth in coming future. The global market is majorly driven by increasing eye cancer patients across the globe. Additionally, increasing smoking population and rising consumption of alcohol have spurred the growth of the market. However, long time for approval, and side effects of the treatment may hinder the growth of the market.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4736

The global eye cancer market is expected to grow at a CAGR of ~8.3 % during the forecast period 2017-2023.

Key Players

Some of key the players in the market are GlaxoSmithKline Plc. (U.K.), AstraZeneca Plc. (U.K.), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (U.S.), Bayer AG (Germany), Amgen, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), , F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), Oncomed Pharmaceuticals (U.S.) and Immunomedics (U.S.).

Segmentation

The global eye cancer market is segmented on the basis of types, treatment and end users.

On the basis of treatment, the market is categorised into chemotherapy, surgery & radiation therapy, targeted therapy, hormone therapy, biologic therapy, and other. Chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents. Target therapy is sub segmented into monoclonal antibodies and tyrosine kinase inhibitors. Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors and others.

On the basis of types, the market is segmented into intraocular cancer, squamous cell cancer, rhabdomyosarcoma, and others. Intraocular cancer is further segmented into melanoma of the eye, lymphoma of the eye, and eye cancers in children.

On the basis of end users, the market is segmented into hospital & clinics, ambulatory care centers and others.

Browse More Details of the Report @https://www.marketresearchfuture.com/reports/eye-cancer-market-4736

COMTEX_377106741/2582/2021-01-02T04:18:23

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

The MarketWatch News Department was not involved in the creation of this content.